506U78 in Treating Patients With Refractory Hematologic Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or
refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor
cells from dividing so they stop growing or die.